Immunogenicity of the inactivated influenza vaccine in children who have undergone allogeneic haematopoietic stem cell transplant
| Autor: | Heather Tapp, Peter Jacoby, Anne L. Ryan, Nicholas G. Gottardo, Ushma D. Wadia, Ian G. Barr, Louise A. Carolan, Laurence C. Cheung, Christopher C Blyth, Peter Richmond, Rishi S. Kotecha, Chris Fraser, Karen L. Laurie, Francoise Mechinaud, Fiona Kerr |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
medicine.medical_specialty
Disease prevention Influenza vaccine medicine.medical_treatment Hematopoietic stem cell transplantation Antibodies Viral medicine.disease_cause Article 03 medical and health sciences Influenza A Virus H1N1 Subtype Clinical trials 0302 clinical medicine Internal medicine Influenza Human Influenza A virus Humans Medicine Prospective Studies Seroconversion Child Adverse effect Transplantation business.industry Influenza A Virus H3N2 Subtype Immunogenicity Australia Hematopoietic Stem Cell Transplantation Paediatrics Hematology Vaccination Vaccines Inactivated Influenza Vaccines 030220 oncology & carcinogenesis business 030215 immunology |
| Zdroj: | Bone Marrow Transplantation |
| ISSN: | 1476-5365 0268-3369 |
| Popis: | Influenza vaccination is recommended for children following allogeneic haematopoietic stem cell transplant (HSCT), however there is limited evidence regarding its benefit. A prospective multicentre study was conducted to evaluate the immunogenicity of the inactivated influenza vaccine in children who have undergone HSCT compared with healthy age-matched controls. Participants were vaccinated between 2013 and 2016 according to Australian guidelines. Influenza-specific hemagglutinin inhibition antibody titres were performed prior to each vaccination and 4 weeks following the final vaccination. A nasopharyngeal aspirate for influenza was performed on participants that developed influenza-like illness. There were 86 children recruited; 43 who had undergone HSCT and 43 controls. For the HSCT group, seroprotection and seroconversion rates were 81.4% and 60.5% for H3N2, 41.9% and 32.6% for H1N1, and 44.2% and 39.5% for B strain respectively. There was a significant geometric mean fold increase to the H3N2 (GMFI 5.80, 95% CI 3.68–9.14, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink